Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

362
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
362
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

320
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
320
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

359
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
359
Positive Symptoms of Schizophrenia: Hallucinations and Delusions01:30

Positive Symptoms of Schizophrenia: Hallucinations and Delusions

211
Schizophrenia is a complex mental health disorder that can manifest with various positive symptoms, including thought, movement, and behavior disorders. These symptoms significantly disrupt cognitive and motor functions, leading to profound effects on an individual's ability to engage with the world.
Thought Disorders
Disorganized and unusual thought processes mark thought disorders in schizophrenia. One key feature is disorganized speech, where an individual's conversation includes...
211
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

560
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
560
Disorders of the Nervous Tissue01:28

Disorders of the Nervous Tissue

1.5K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reach of Palliative Care in Parkinson Disease: Progress and Gaps After a National Team-Based Implementation Project.

Neurology. Clinical practice·2026
Same author

Embedding Palliative Care Clinicians in ALS Teams Improves ALS Clinicians' Confidence in Their Patient Management and Satisfaction With Palliative Care.

Muscle & nerve·2026
Same author

Workplace Lactation in Neurology: Barriers and Opportunities.

Neurology. Clinical practice·2026
Same author

A 360 Degree Qualitative Ethical Assessment of Reporting Patient Reported Outcomes.

Journal of empirical research on human research ethics : JERHRE·2026
Same author

Domains of Caregiving in Parkinson's Disease: A Framework Developed Through Perspective Mapping.

The American journal of hospice & palliative care·2026
Same author

Healthcare Utilization Patterns of Persons Living with Parkinson's Disease and Related Disorders with Moderate to High Palliative Care Needs.

Movement disorders clinical practice·2026

Related Experiment Video

Updated: Aug 30, 2025

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

156

Cannabinoids in movement disorders.

Benzi M Kluger1, Andrew P Huang1, Janis M Miyasaki2

  • 1Departments of Neurology and Medicine, University of Rochester Medical Center, Rochester, NY, USA.

Parkinsonism & Related Disorders
|August 29, 2022
PubMed
Summary

Cannabis shows potential for movement disorders, but clinical evidence is inconclusive and safety concerns remain. More research is needed to determine the true benefits and long-term effects of medical cannabis for these conditions.

Keywords:
CannabinoidsHuntington's diseaseMarijuanaParkinson's diseaseTourette's syndrome

More Related Videos

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.6K
Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

6.8K

Related Experiment Videos

Last Updated: Aug 30, 2025

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

156
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.6K
Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

6.8K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Movement Disorders

Background:

  • Growing optimism surrounds cannabis and cannabinoids for treating movement disorders.
  • Skepticism exists regarding the scientific basis and safety of cannabinoid products, especially unregulated ones.

Purpose of the Study:

  • To summarize the key findings from a talk on cannabis at the 2019 International Parkinson and Movement Disorders Society annual meeting.
  • To address the controversies and current understanding of cannabis in movement disorder treatment.

Main Methods:

  • Review of a plenary session talk from the 2019 International Parkinson and Movement Disorders Society annual meeting.
  • Synthesis of current scientific understanding and clinical research on cannabinoids for movement disorders.

Main Results:

  • The endocannabinoid system is linked to motor function, offering potential therapeutic targets.
  • Clinical research on cannabinoids for Parkinson's, Huntington's, Tourette's, and dystonia is largely inconclusive or negative.
  • Cannabinoids may be effective for pain, but long-term effects in older adults with movement disorders are unknown. Risks include falls and apathy.

Conclusions:

  • Further research is essential to clarify the clinical benefits of medical cannabis for movement disorders.
  • Long-term side effects and efficacy in specific patient populations require thorough investigation.